Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial results for the year ended December 31, 2024 and provides updates on key clinical and commercial ...
FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
2d
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today ...
Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles ...
Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ETCompany ParticipantsZack Armen - Head of Investor Relations, ...
The manufacturing industry is undergoing another profound transformation towards “Smart Manufacturing”, characterized by Industry 4.0 and digitalisation. The Master of Science in Smart Manufacturing ...
SUZHOU, China I March 5, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer ...
Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...
Issued on behalf of Oncolytics Biotech Inc. At ASCO GI, Oncolytics also shared encouraging data on relapsed anal cancer. Of 12 evaluable patients, four experienced a partial response, translating to a ...
Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback